Member Info for allah4uk

You have to understand, they're too busy unpicking the GFA !

Yeah, earlier there was speculation that Thermofisher was NCYT's US OEM - but no conclusive proof.

Salam Kimbo.

Looking at this link : https://www.thermofisher.com/order/catalog/product/R12550#/R12550

It appears that no, it doesn't mean that. They might or might not use Thermofisher's own test, depengding on whether they sourced these tubes standalone or as part of a bigger package.

From the Graun's article : "Answering questions from the Commons health and social care committee, the health secretary, Matt Han****, said there had been “operational issues” connected to contracts to carry out tests, adding: “It’s a matter of a couple of weeks until we can get all of that sorted in the short term.”"

Eh, hopefully the issue lies with the lab managers - and not the test providers (or at least not us).

By the way, if we go by Graham's three-pillar growth strategy :

"Novacyt is focused on three strategic pillars of growth, those being Organic growth, Innovative R&D and Acquisition."

The current workforce acquisition covers the first two : organic growth especially (lots of salesmen -> hopefully increasing market share), but also innovative R&D (cf. Head of Product Management current job advert).

I can't repeat it enough : management is a crucial part of a company !
Never overlook the top managers when you assess the value of a company !!!

Quality management is what makes the difference between NCYT which has developed good coronavirus products *and* sold millions of them, thanks to its timely operation from concept to market approval... and GDR which also came up with a good coronavirus test *but* has sold exactly ZERO items, nine months (!) after the beginning of the pandemic.

Saintsmith : the lowest value that I found for a Bri'ish midcap is <1bn£.

Oxford BioMedica, in the FTSE 250, market cap 706m£.

So...

"In our view the most significant challenge with such growth prospects is the timely hiring of the right people and their integration into the organisation. Already this year we have hired in excess of 50 people in the UK.

We are focusing significant efforts in talent acquisition to ensure we identify and source people who share the same ambition and attitude, and have the specific skills we need to grow. "

https://www.sharebuyers.co.uk/shares/novacyt-shares-going-for-growth-poised-for-mid-cap-stardom/

Looks like my hypothesis is right. Doesn't matter whether we have a giant contract or not - we've got the money already, and we're investing it into people.

That falls on a saturday, zo.

Bladesharp is such a cheeky bruv !

Now my question for him is : are we talking, 6, 7 or even 8 figures ?

The suspense is unbearable, he he.

Anyone with a Twatter account can ping that article to @PrimerdesignLtd ?

We have 4 distributors in Korea, but it can't hurt to remind Novacyt's Asia sales team of that country's acute need for our novel test.

https://edition.cnn.com/world/live-news/coronavirus-pandemic-09-07-20-intl/h_ca6f4971b686dfddfb5b4f1d23c419aa

"South Korea is developing a testing kit that can detect seasonal flu and Covid-19 at the same time, according to the country's Centers for Disease Control and Prevention (KCDC)

As symptoms of Covid-19 and seasonal flu are similar it's important to detect the difference for the coming fall flu season, KCDC director Jung Eun-kyeong said at a news conference on Monday.

South Korea’s Ministry of Food and Drug Safety is currently going through the permit process to approve the test. The kit will allow detection of either virus from a single sample, Jung said."

Reiterating my guess that the antibody test announcement could therefore occur before the 17th.

WHY DO YOU WRITE IN CAPS

Monty11 : Yep, it's not a definitive proof that we've won a contract. It could merely mean that we're serious about selling to the NHS.

Bladesharp : first, thanks for sharing your find.
Regarding the 13 new territory managers, Graham could be willing to field them even before we've landed any major contract. The reasoning being that there's never been a better time to aggressively seek new customers, and that we're now in the financial position to do so.

That's small time bruv, it's more than double this figure over here.

Speaking about which, I was tabling on an an antibody RNS announcement around late October/early November ; but maybe it'll come before the 17th of October then.

Obviously the single most important piece of information that'll up the SP will be sales numbers.

However a large contract announced in-between would also propel the SP.

We all expected a proper rerate today, thanks to the positive perspectives of this RNS.
It started well but then fell flat. Or did it ?

Bruvs, I know you're naturally focused on the AIM since it's a Bri'ish board.
Let's see :
NCYT : 0%
AVCT : -1,20 %
ODX : -6,14 % (!)
GDR : 6,15 %

So, not such a good day overall for the corona stocks.
GDR is an outlier. They received some good news... err actually no, I checked and no RNS landed today. Turns out they reacted over a rumour of getting an FDA approval ; they digged a document on the company's website... which, in fact, had been there for weeks.

But if you look at Alternext, things are better.
ALNOV : + 2,28 %
Eurobio : 0 %
Biosynex : -2,72 %

See, we didn't do nearly as well as expected, but overall the news still had some positive impact.

Let's face it Daveri007, you're blatantly talking out of your a.rse without an ounce of shame.
This tells a lot about you.

Since you're so keen on mentionning the French, here's a French proverb which applies to you : « Les cons ça ose tout, c'est même à ça qu'on les reconnaît ».

Al69lah, I'm primarily digging at the Bourso mongos who followed suit.
Not sure about Anglos, I don't think many of your kind browse French forums in the first place.

I wonder when the first sales update will be, guessing around December.